Anti-factor XII / XIIa antibodies and uses thereof

Abstract

The present invention provides monoclonal antibodies that bind to factor XII (FXII) protein and methods for their use. In various embodiments of the present invention, the antibodies are fully human antibodies that bind to FXII and the activated form of FXII (FXIIa). In some embodiments, the antibodies of the present invention are useful for inhibiting or neutralizing FXII activity, thus providing a means for treating or preventing diseases, disorders, or conditions related to thrombosis in humans.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This invention claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 687,144, filed June 19, 2018, the entire contents of which are incorporated herein by reference.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on June 18, 2019, is named 10463WO01_SL.txt and is 26,288 bytes in size.

[0003] The present invention relates to antibodies and antigen-binding fragments of antibodies that specifically bind to coagulation factor XII, and to therapeutic and diagnostic methods using those antibodies. [Background technology]

[0004] Coagulation factors, together with platelets, are blood components involved in the process of hemostasis during vascular injury. It is well established that these components, if imbalanced in regulation (i.e., production and / or activity), can be drivers of thrombosis. Thrombotic diseases were thought to result primarily from aberrant activation in the extrinsic pathway (via tissue factor), but more recently, preclinical studies with F12-deficient mice and molecules targeting activated FXII (FXIIa) have suggested that the intrinsic pathway of coagulation (also known as the contact pathway) is also involved (Renne et al. 2005, J. Exp. Med. 202:271-81; Larsson et al. 2014, Sci. Transl. Med. 6:222ra17). FXIIa is central to the contact pathway and can promote coagulation via cleavage of FXI or inflammation via cleavage of plasma prekallikrein. Thus, inhibition of FXII activity may lead to a reduction in thrombotic coagulation and inflammation associated with activation of the contact pathway (Schousboe 2007, Biochem. Pharmacol. 75:1007-13; Danese et al 2016, Semin. Thromb. Hemostat. 42:682-8; Weitz 2016, Thromb. Res. 141 Suppl. 2:S40-5). Anticoagulants currently used in the art, such as heparin, are effective antithrombotic agents, but they also increase the risk of bleeding. Therefore, it is desirable to develop anticoagulants that prevent thrombosis without increasing the risk of bleeding. Monoclonal antibodies against FXII are known in the art and are described, for example, in U.S. Patent / Publication Nos. 4,963,657, 5,500,349, 8,119,137, 8,715,672, 9,856,326, 9,856,325, 9,518,127, 2013 / 0095108, 2014 / 0072572, 2014 / 0072600, as well as WO 2006 / 066878, WO 2013 / 014092, EP 1830924 B1, EP 27345522 A1, and EP 2623110 A1. Fully human antibodies that specifically bind to (activated) FXII protein with high affinity and prevent thrombosis without increasing the risk of bleeding may be important in the prevention and treatment of various FXII-related diseases (e.g., thrombosis, embolism, edema). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] U.S. Pat. No. 4,963,657 [Patent Document 2] U.S. Pat. No. 5,500,349 [Patent Document 3] U.S. Patent No. 8,119,137 [Patent Document 4] U.S. Patent No. 8,715,672 [Patent Document 5] U.S. Pat. No. 9,856,326 [Patent Document 6] U.S. Patent No. 9,856,325 [Patent Document 7] U.S. Patent No. 9,518,127 [Patent Document 8] US Patent Application Publication No. 2013 / 0095108 [Patent Document 9] US Patent Application Publication No. 2014 / 0072572 [Patent Document 10] US Patent Application Publication No. 2014 / 0072600 [Patent Document 11] International Publication No. 2006 / 066878 [Patent Document 12] International Publication No. 2013 / 014092 [Patent Document 13] European Patent No. 1830924 [Patent Document 14] European Patent Application Publication No. 27345522 [Patent Document 15] European Patent Application Publication No. 2623110

Non-Patent Literature

[0006]

Non-Patent Literature 1

Non-Patent Literature 2

Non-Patent Literature 3

Non-Patent Literature 4

Non-Patent Literature 5

Summary of the Invention

[0007] The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to the activated form of coagulation factor XII protein (FXIIa). In certain embodiments, the antibodies also bind to the zymogen form of factor XII (FXII). In certain embodiments, the antibodies are fully human antibodies that also bind to FXII and FXIIa ("dual FXII / FXIIa binders") with high affinity. The antibodies of the present invention are useful, inter alia, for inhibiting or neutralizing the activity of FXII protein. In certain embodiments, the antibodies are useful for preventing, treating, or ameliorating at least one symptom or sign of a FXII-related disease or disorder in a subject. In certain embodiments, the antibodies may be administered prophylactically or therapeutically to a subject having or at risk for a FXII-related disease or disorder. In certain preferred embodiments. In certain embodiments, the antibodies prevent thrombosis without increasing the risk of bleeding in the subject. Such antibodies can be used as anticoagulant therapy in subjects with FXII-related diseases or disorders with reduced dosing frequency and without increasing the risk of bleeding when administered to a subject in need thereof.

[0008] The antibodies of the invention may be full length (e.g., IgG1 or IgG4 antibodies) or may be antigen-binding portions (e.g., Fab, F(ab') 2 or scFv fragments) and may be modified to affect functionality, for example to increase persistence in the host or to eliminate residual effector function (Reddy et al., 2000, J. Immunol. 164:1925-1933). In certain embodiments, the antibody may be bispecific.

[0009] In a first aspect, the present invention provides an isolated recombinant monoclonal antibody or antigen-binding fragment thereof that specifically binds to factor XII (FXII) and / or activated factor XII (FXIIa). In some embodiments, the antibody is a fully human monoclonal antibody. In certain embodiments, the antibody is a "dual binder" capable of binding to FXII and FXIIa.

[0010] Exemplary anti-FXII / FXIIa antibodies of the invention are listed in Tables 1 and 2 herein. Table 1 shows the amino acid sequence identifiers of the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementarity determining region (HCDR) (HCDR1, HCDR2, and HCDR3), and light chain complementarity determining region (LCDR) (LCDR1, LCDR2, and LCDR3) of the exemplary antibodies. Table 2 shows the nucleic acid sequence identifiers of the HCVR, LCVR, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the exemplary antibodies.

[0011] The present invention provides antibodies or antigen-binding fragments thereof, comprising an HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0012] The present invention also provides antibodies or antigen-binding fragments thereof, comprising an LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0013] The present invention also provides antibodies or antigen-binding fragments thereof, comprising HCVR and LCVR amino acid sequence pairs (HCVR / LCVR) comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies or antigen-binding fragments thereof, comprising an HCVR / LCVR amino acid sequence pair comprised within any of the exemplary anti-FXII / FXIIa antibodies listed in Table 1. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from one of SEQ ID NOs: 2 / 10 (e.g., mAb26036), 18 / 26 (e.g., mAb26048), 34 / 42 (e.g., mAb26049), or 50 / 58 (e.g., mAb26076).

[0014] The invention also provides antibodies or antigen-binding fragments thereof comprising an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence listed in Table 1 with no more than 12 amino acid substitutions, and / or the LCVR comprises an amino acid sequence listed in Table 1 with no more than 10 amino acid substitutions. For example, the invention provides antibodies or antigen-binding fragments thereof comprising an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, wherein the amino acid sequence has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid substitutions. In another embodiment, the invention provides antibodies or antigen-binding fragments thereof comprising an HCVR and an LCVR, wherein the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, wherein the amino acid sequence has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions. In one embodiment, the present invention provides an anti-FXII / FXIIa antibody or antigen-binding fragment thereof comprising an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, and the amino acid sequence has at least one amino acid substitution, and / or the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, and the amino acid sequence has at least one amino acid substitution.

[0015] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0016] The present invention also provides an antibody or antigen-binding fragment thereof, comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0017] The present invention also provides an antibody or antigen-binding fragment thereof, comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0018] The present invention also provides an antibody or antigen-binding fragment thereof, comprising a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0019] The present invention also provides an antibody or antigen-binding fragment thereof, comprising a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0020] The present invention also provides an antibody or antigen-binding fragment thereof, comprising a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0021] The present invention also provides an antibody or antigen-binding fragment thereof, comprising an HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3) comprising any of the HCDR3 amino acid sequences listed in Table 1 paired with any of the LCDR3 amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides an antibody or antigen-binding fragment thereof, comprising an HCDR3 / LCDR3 amino acid sequence pair comprised in any of the exemplary anti-FXII antibodies listed in Table 1. In certain embodiments, the HCDR3 / LCDR3 amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 8 / 16 (e.g., mAb26036), 24 / 32 (e.g., mAb26048), 40 / 48 (e.g., mAb26049), and 56 / 64 (e.g., mAb26076).

[0022] The invention also provides an antibody or antigen-binding fragment thereof comprising an HCVR and an LCVR, wherein the HCVR comprises an HCDR1 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, an HCDR2 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, and an HCDR3 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1. In a particular embodiment, the invention provides an antibody or antigen-binding fragment thereof comprising an HCVR and an LCVR, wherein the LCVR comprises an LCDR1 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, an LCDR2 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, and an LCDR3 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1. For example, the invention provides an antibody or antigen-binding fragment thereof comprising an HCVR and an LCVR, wherein the HCVR comprises an HCDR1 comprising an amino acid sequence of SEQ ID NO:4 or an amino acid sequence that differs by one amino acid from SEQ ID NO:4, an HCDR2 comprising an amino acid sequence of SEQ ID NO:6 or an amino acid sequence that differs by one amino acid from SEQ ID NO:6, and an HCDR3 comprising an amino acid sequence of SEQ ID NO:8 or an amino acid sequence that differs by one amino acid from SEQ ID NO:8. In another exemplary embodiment, the invention provides an antibody or antigen-binding fragment thereof comprising an HCVR and an LCVR, wherein the LCVR comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 16.

[0023] The present invention also provides an antibody or antigen-binding fragment thereof, comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any of the exemplary antibodies listed in Table 1. In certain embodiments, the amino acid sequence set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 is selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16 (e.g., mAb26036), 20-22-24-28-30-32 (e.g., mAb26048), 36-38-40-44-46-48 (e.g., mAb26049), and 52-54-56-60-62-64 (e.g., mAb26076).

[0024] In a related embodiment, the present invention provides an antibody or antigen-binding fragment thereof, comprising a set of six CDRs (e.g., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in the HCVR / LCVR amino acid sequence pair defined by any of the exemplary antibodies listed in Table 1. For example, the present invention comprises an antibody or antigen-binding fragment thereof, comprising a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences contained in the HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10 (e.g., mAb26036), 18 / 26 (e.g., mAb26048), 34 / 42 (e.g., mAb26049), or 50 / 58 (e.g., mAb26076). Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specific HCVR and / or LCVR amino acid sequences disclosed herein. Exemplary rules that can be used to identify the boundaries of CDRs include, for example, the Kabat definition, the Chothia definition, and the AbM definition. Generally speaking, the Kabat definition is based on sequence diversity, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, for example, Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273: 927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86: 9268-9272 (1989). Public databases are also available to identify CDR sequences within antibodies.

[0025] In certain embodiments, the invention includes an antibody or antigen-binding fragment thereof that specifically binds to FXII and / or FXIIa, the antibody or antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR), the HCVR comprising: (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; (ii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; (iii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; and the LCVR comprises (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, (ii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, (iii) an amino acid sequence having at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, or (iv) an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58 with no more than 10 amino acid substitutions.

[0026] The present invention includes anti-FXII / FXIIa antibodies with modified glycosylation patterns. In some embodiments, modifications to remove undesired glycosylation sites or antibodies lacking fucose moieties present on the oligosaccharide chains may be useful, for example, to increase antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277:26733). In other applications, modifications of galactosylation can be made to modify complement-dependent cytotoxicity (CDC).

[0027] In certain embodiments, the present invention provides antibodies and antigen-binding fragments thereof that exhibit pH-dependent binding to FXII. For example, the present invention includes antibodies and antigen-binding fragments thereof that bind to FXII with higher affinity at neutral pH than at acidic pH (i.e., reduced binding at acidic pH).

[0028] The present invention also provides antibodies and antigen-binding fragments thereof that compete with an antibody or antigen-binding fragment thereof comprising a CDR of an HCVR and a CDR of an LCVR for specific binding to FXII or FXIIa, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively.

[0029] The present invention also provides antibodies and antigen-binding fragments thereof that cross-compete with a reference antibody or antigen-binding fragment thereof comprising a CDR of an HCVR and a CDR of an LCVR for binding to FXII / FXIIa, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively.

[0030] The present invention also provides antibodies and antigen-binding fragments thereof that bind to the same epitope as a reference antibody or antigen-binding fragment thereof that comprises three CDRs of an HCVR and three CDRs of an LCVR, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively.

[0031] In some embodiments, the antibody or antigen-binding fragment thereof may specifically bind to FXII and / or FXIIa in an agonistic manner, i.e., enhance or stimulate FXII / FXIIa binding and / or activity, while in other embodiments, the antibody may specifically bind to FXII and / or FXIIa in an antagonistic manner, i.e., block FXII binding and / or activity.

[0032] The present invention also provides an isolated antibody or antigen-binding fragment thereof that blocks FXIIa binding to FXI. In some embodiments, the antibody or antigen-binding fragment thereof that blocks FXIIa binding to FXI may bind to the same epitope on FXIIa as FXI, or may bind to a different epitope on FXIIa than FXI.

[0033] In certain embodiments, the antibodies or antigen-binding fragments of the present invention are bispecific and comprise a first binding specificity for a first epitope of FXII / FXIIa and a second binding specificity for a second epitope of FXII / FXIIa, wherein the first epitope and the second epitope are distinct and non-overlapping.

[0034] In certain embodiments, the present invention provides an isolated antibody or antigen-binding fragment thereof having one or more of the following characteristics: (a) is a fully human monoclonal antibody; (b) binds to activated factor XII (FXIIa); and (c) has a dissociation constant (K) of less than 3.5 nM at 25° C. as measured in a surface plasmon resonance assay. D ) and binds to FXII; (d) has a K of less than 17 nM at 37° C. as measured in a surface plasmon resonance assay. D and binds to FXII at 25° C. with a K of less than 5 nM, preferably less than 2.5 nM, as measured in a surface plasmon resonance assay. D (f) a K of less than 6.5 nM, preferably less than 2.5 nM, at 37° C., as measured in a surface plasmon resonance assay. D (g) blocks thrombin generation by the intrinsic pathway at concentrations less than 250 nM, as measured by a functional plasma assay; and (h) blocks thrombin generation by the intrinsic pathway without blocking thrombin generation by the extrinsic pathway, as measured by a functional plasma assay.

[0035] In a second aspect, the present invention provides a nucleic acid molecule encoding an anti-FXII / FXIIa antibody or a portion thereof. For example, the present invention provides a nucleic acid molecule encoding any of the HCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0036] The present invention also provides nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0037] The present invention also provides a nucleic acid molecule encoding any of the HCDR1 amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0038] The present invention also provides nucleic acid molecules encoding any of the HCDR2 amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0039] The present invention also provides nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0040] The present invention also provides a nucleic acid molecule encoding any of the LCDR1 amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0041] The present invention also provides nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0042] The present invention also provides a nucleic acid molecule encoding any of the LCDR3 amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0043] The present invention also provides a nucleic acid molecule encoding an HCVR, which comprises a set of three CDRs (i.e., HCDR1-HCDR2-HCDR3), where the HCDR1-HCDR2-HCDR3 amino acid sequence set is defined by any of the exemplary antibodies listed in Table 1.

[0044] The present invention also provides a nucleic acid molecule encoding an LCVR, which comprises a set of three CDRs (i.e., LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid sequence set is defined by any of the exemplary antibodies listed in Table 1.

[0045] The invention also provides nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises any of the HCVR amino acid sequences listed in Table 1, and the LCVR comprises any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes an HCVR and an LCVR, both of which are derived from the same anti-FXII antibody listed in Table 1.

[0046] In a related aspect, the invention provides a recombinant expression vector capable of expressing a polypeptide comprising a heavy or light chain variable region of an antibody. For example, the invention includes a recombinant expression vector comprising any of the above-mentioned nucleic acid molecules, i.e., any of the HCVR, LCVR, and / or CDR sequences listed in Table 2. In certain embodiments, the invention provides an expression vector comprising: (a) a nucleic acid molecule comprising a nucleic acid sequence encoding an HCVR of an antibody that binds to FXII / FXIIa, wherein the HCVR comprises an amino acid sequence selected from the group consisting of the sequences listed in Table 1; and / or (b) a nucleic acid molecule comprising a nucleic acid sequence encoding an LCVR of an antibody that binds to FXII / FXIIa, wherein the LCVR comprises an amino acid sequence selected from the group consisting of the sequences listed in Table 1. Also included are host cells into which such vectors have been introduced, as well as methods of producing an antibody or a portion thereof by culturing the host cell under conditions that allow for the production of the antibody or antibody fragment, and recovering the antibody and antibody fragment so produced. In certain embodiments, the host cell comprises a mammalian cell or a prokaryotic cell. In certain embodiments, the host cell is a Chinese Hamster Ovary (CHO) cell or an Escherichia coli (E. coli) cell. In certain embodiments, the invention provides a method of producing an antibody or antigen-binding fragment thereof of the invention, comprising introducing into a host cell an expression vector comprising a nucleic acid sequence encoding the HCVR and / or LCVR of the antibody or antigen-binding fragment thereof operably linked to a promoter, culturing the host cell under conditions favorable for expression of the nucleic acid sequence, and isolating the antibody or antigen-binding fragment thereof from the culture medium and / or the host cell. The isolated antibody or antigen-binding fragment thereof may be purified using any of the methods known in the prior art.

[0047] In a third aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one recombinant monoclonal antibody or antigen-binding fragment thereof that specifically binds to FXII / FXIIa, and a pharma- ceutically acceptable carrier. In a related aspect, the invention features a composition that is a combination of an anti-FXII / FXIIa antibody and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with an anti-FXII / FXIIa antibody. Exemplary agents that can be advantageously combined with an anti-FXII / FXIIa antibody include, but are not limited to, other agents that bind and / or inhibit FXII activity (including other antibodies or antigen-binding fragments thereof, etc.), and / or agents that do not directly bind to FXII but still treat or ameliorate at least one symptom or sign of a FXII-associated disease or disorder. Additional combination therapies and coformulations that include the anti-FXII antibodies of the invention are disclosed elsewhere herein.

[0048] In a fourth aspect, the present invention provides therapeutic methods for treating a disease or disorder associated with FXII in a subject using an anti-FXII / FXIIa antibody or antigen-binding portion of the antibody of the present invention, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an antibody or antigen-binding fragment of the antibody of the present invention. The disorder to be treated is any disease or condition that is improved, ameliorated, blocked, or prevented by inhibition of FXII activity. In certain embodiments, the present invention provides a method for preventing or treating a FXII-related disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of an anti-FXII / FXIIa antibody or antigen-binding fragment of the present invention. In some embodiments, the antibody or antigen-binding fragment of the present invention may be administered prophylactically or therapeutically to a subject having or at risk for a FXII-related disease or disorder. In certain embodiments, the antibody or antigen-binding fragment of the present invention is administered to a subject in need thereof in combination with a second therapeutic agent. The second therapeutic agent may be selected from the group consisting of anticoagulants, direct thrombin inhibitors, thrombolytic drugs, fibrinolytic drugs, antiplatelet drugs, anti-inflammatory drugs, antihypertensive drugs, second anti-FXII antibodies, lipid-lowering drugs, mechanical clot retrieval, catheter-induced thrombolysis, compression stockings, surgery, and any other drug or therapy known in the art. In certain embodiments, the second therapeutic agent may be an agent that serves to offset or reduce possible side effect(s) associated with the antibody or antigen-binding fragment thereof of the present invention, if such side effect(s) occur. The antibody or fragment thereof may be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, or intramuscularly. The antibody or fragment thereof may be administered at a dose of about 0.1 mg / kg to about 100 mg / kg of the subject's body weight. In certain embodiments, the antibody of the present invention may be administered in one or more doses including 10 mg to 600 mg.

[0049] The present invention also includes the use of an anti-FXII / FXIIa antibody or antigen-binding fragment thereof of the present invention in the manufacture of a medicament for the treatment of a disease or disorder that would benefit from blocking FXII / FXIIa binding and / or activity.

[0050] Other embodiments will become apparent from review of the following detailed description. In certain embodiments, for example, the following are provided: (Item 1) An antibody or antigen-binding fragment thereof that specifically binds to factor XII (FXII), having the following characteristics: (a) is a fully human monoclonal antibody; (b) binds to activated factor XII (FXIIa); (c) a dissociation constant (K) of less than 3.5 nM at 25° C. as measured by surface plasmon resonance assay; D ) and binds to FXII. (d) a K of less than 17 nM at 37° C. as measured by a surface plasmon resonance assay D And binds to FXII, (e) a K of less than 5 nM, preferably less than 2.5 nM, at 25° C., as measured by a surface plasmon resonance assay. D and binds to FXIIa. (f) a K of less than 6.5 nM, preferably less than 2.5 nM, at 37° C. as measured in a surface plasmon resonance assay; D and binds to FXIIa. (g) blocks thrombin generation by the intrinsic pathway at concentrations less than 250 nM as measured by a functional plasma assay; and (h) blocking thrombin generation via the intrinsic pathway without blocking thrombin generation via the extrinsic pathway, as measured by a functional plasma assay. (Item 2) The antibody or antigen-binding fragment of item 1, wherein the antibody or antigen-binding fragment comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR), and the HCVRs have an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1. (Item 3) The antibody or antigen-binding fragment thereof according to item 2, comprising an LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1. (Item 4) (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, and 52; (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, and 54; (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, and 56; (d) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, and 60; (e) an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, and 62; (f) an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, and 64. (Item 5) The antibody or antigen-binding fragment thereof of item 4, comprising CDRs selected from the group consisting of: (a) SEQ ID NOs: 4, 6, 8, 12, 14, and 16; (b) SEQ ID NOs: 20, 22, 24, 28, 30, and 32; (c) SEQ ID NOs: 36, 38, 40, 44, 46, and 48; and (d) SEQ ID NOs: 52, 54, 56, 60, 62, and 64. (Item 6) 6. The antibody or antigen-binding fragment thereof of item 5, comprising an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, and 50 / 58. (Item 7) An antibody or antigen-binding fragment thereof that binds to FXII / FXIIa, the antibody or antigen-binding fragment thereof comprising three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within an HCVR and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within an LCVR, the HCVR comprising: (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; (ii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; (iii) an amino acid sequence having at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; or (iv) an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, having no more than 12 amino acid substitutions; The LCVR is (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; (ii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; (iii) an amino acid sequence having at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; or (iv) An antibody or antigen-binding fragment thereof comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, and having no more than 10 amino acid substitutions. (Item 8) 8. The antibody or antigen-binding fragment thereof of item 7, comprising an HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50. (Item 9) 8. The antibody or antigen-binding fragment thereof of item 7, comprising an LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58. (Item 10) 10. The antibody or antigen-binding fragment thereof according to any one of items 7 to 9, comprising three CDRs contained within the HCVR selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, and three CDRs contained within the LCVR selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58. (Item 11) 11. The antibody or antigen-binding fragment according to any one of items 7 to 10, comprising a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, and 50 / 58. (Item 12) (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, and 52; (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, and 54; (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, and 56; (d) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, and 60; (e) an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, and 62; (f) an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, and 64. (Item 13) 13. The antibody or antigen-binding fragment thereof of item 12, comprising CDRs selected from the group consisting of: (a) SEQ ID NOs: 4, 6, 8, 12, 14, and 16; (b) SEQ ID NOs: 20, 22, 24, 28, 30, and 32; (c) SEQ ID NOs: 36, 38, 40, 44, 46, and 48; and (d) SEQ ID NOs: 52, 54, 56, 60, 62, and 64. (Item 14) 14. The antibody or antigen-binding fragment thereof of item 13, comprising an HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50. (Item 15) 14. The antibody or antigen-binding fragment thereof of item 13, comprising an LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58. (Item 16) 16. The antibody or antigen-binding fragment thereof according to any one of items 12 to 15, comprising an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, and 50 / 58. (Item 17) 17. An antibody or antigen-binding fragment thereof that competes with the antibody or antigen-binding fragment thereof according to any one of items 1 to 16 for binding to factor XII. (Item 18) 17. An antibody or antigen-binding fragment thereof that binds to the same epitope as the antibody or antigen-binding fragment thereof according to any one of items 1 to 16. (Item 19) An isolated monoclonal antibody or antigen-binding fragment thereof which blocks cleavage of factor XII to FXIIa and FXIIb, comprising three CDRs of HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, and three CDRs of LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58. (Item 20) 20. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that binds to factor XII / XIIa according to any one of items 1 to 19, and a pharma- ceutically acceptable carrier or diluent. (Item 21) 20. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the HCVR of the antibody according to any one of items 1 to 19. (Item 22) 20. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the LCVR of the antibody according to any one of items 1 to 19. (Item 23) 23. A vector comprising the polynucleotide sequence according to item 21 or 22. (Item 24) A host cell expressing the vector according to item 23. (Item 25) A method for producing an anti-FXII / FXIIa antibody or an antigen-binding fragment thereof, comprising growing a host cell described in item 24 under conditions that allow production of the antibody or fragment, and recovering the antibody or fragment so produced. (Item 26) 26. The method of claim 25, further comprising formulating the antibody or antigen-binding fragment thereof as a pharmaceutical composition comprising an acceptable carrier. (Item 27) 20. A method for preventing the formation of a thrombus or treating a subject at risk of thrombus formation, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to any one of items 1 to 19. (Item 28) 28. The method of item 27, wherein the subject has a disease, disorder, or condition selected from the group consisting of venous thrombosis, arterial thrombosis, device thrombosis, thromboembolism, hereditary angioedema, stroke, thrombotic predisposition, cardiac ischemia, atherosclerotic plaque rupture, use of a mechanical valve prosthesis, use of a blood-contacting medical device, use of a blood-contacting extracorporeal circuit, venous thromboembolism, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, Budd-Chiari syndrome, Paget-Schletter disease, renal vein thrombosis, cerebral venous sinus thrombosis, jugular vein thrombosis, cavernous sinus thrombosis, hepatic artery thrombosis, lower limb ischemia, and myocardial infarction. (Item 29) 29. The method according to item 27 or 28, wherein the pharmaceutical composition is administered prophylactically or therapeutically to the subject in need thereof. (Item 30) 30. The method according to any one of items 27 to 29, wherein the pharmaceutical composition is administered in combination with a second therapeutic agent. (Item 31) 31. The method of claim 30, wherein the second therapeutic agent is selected from the group consisting of anticoagulants, direct thrombin inhibitors, thrombolytic drugs, fibrinolytic drugs, antiplatelet drugs, anti-inflammatory drugs, antihypertensive drugs, a second anti-FXII antibody, a lipid-lowering drug, mechanical clot retrieval, catheter-induced thrombolysis, compression stockings, and surgery. (Item 32) 32. The method according to any one of items 27 to 31, wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, or intramuscularly. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] Detailed Description Before describing the method, it should be understood that the present invention is not limited to the particular methods and experimental conditions described, since such methods and conditions may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention is limited only by the appended claims.

[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.Although any method and material similar or equivalent to those described herein can be used to carry out or test this invention, the preferred method and material will now be described.All publications mentioned herein are incorporated herein by reference in their entirety.

[0053] definition The term "FXII" refers to coagulation factor XII, also called "factor XII" and known as Hageman factor. The 596 amino acid FXII protein is the zymogen form of factor XIIa, a β-globulin plasma serine protease consisting of an amino-terminal heavy chain and a carboxy-terminal light chain. The heavy chain contains two fibronectin-type domains (types I and II), two epidermal growth factor-like domains, a kringle domain, and a proline-rich region, and the light chain contains a protease domain. Exposure of blood to negatively charged substances or artificial surfaces triggers thrombin generation and fibrin formation through a series of reactions known as contact activation. Factor XII activates factor XI and prekallikrein in the coagulation cascade. Factor XII itself is activated to factor XIIa by plasma kallikrein, platelet or bacterial polyphosphate, extracellular DNA or RNA, heparin released from mast cells, amyloid peptides, misfolded protein aggregates, and negatively charged surfaces such as glass. This is the starting point of the intrinsic pathway. The amino acid sequence of the full-length FXII protein is exemplified by the amino acid sequence provided in UniProtKB / Swiss-Prot under accession number P00748.3. The amino acid sequence of the full-length FXII protein is also set forth herein as SEQ ID NO: 65. The term "FXII" includes recombinant FXII proteins or fragments thereof. The term also encompasses FXII proteins or fragments thereof bound to a signal sequence, such as, for example, a histidine tag, mouse or human Fc, or ROR1.

[0054] The term "antibody", as used herein, includes immunoglobulin molecules composed of four polypeptide chains, two heavy (H) chains and two light (L) chains, inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM) or antigen-binding fragments thereof. Each heavy chain contains a heavy chain variable region ("HCVR" or "V H ") and the heavy chain constant region (domain C H 1. C H 2 and C H Each light chain is composed of a light chain variable region ("LCVR" or "V L ") and the light chain constant region (C L ) is included. V H Area and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with regions that are more conserved, called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged in the following order from amino terminus to carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the present invention, the FRs of an antibody (or an antigen-binding fragment thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on the parallel analysis of two or more CDRs.

[0055] Substitution of one or more CDR residues or omission of one or more CDRs is also possible. In the scientific literature, it is described that one or two CDRs can be omitted for antibody binding. Padlan et al. (1995 FASEB J.9:133-139) analyzed the contact areas between antibodies and their antigens based on published crystal structures and concluded that only about one-fifth to one-third of the CDR residues actually contact the antigen. Padlan also found many antibodies in which one or two CDRs have no amino acids that contact the antigen (see also Vajdos et al.2002 J Mol Biol 320:415-428).

[0056] CDR residues that do not contact the antigen can be identified from regions of the Kabat CDRs that lie outside the Chothia CDRs, based on previous studies, by molecular modeling and / or empirically (e.g., residues H60-H65 of CDRH2 are often not necessary). When a CDR or its residue(s) is omitted, it is usually replaced with an amino acid that occupies the corresponding position in another human antibody sequence or a consensus of such a sequence. The positions for substitution within the CDR and the substituting amino acid can also be selected empirically. The empirical substitution can be a conservative or non-conservative substitution.

[0057] The fully human anti-FXII monoclonal antibodies disclosed herein may contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The present invention includes antibodies and antigen-binding fragments thereof derived from any of the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue(s) in the germline sequence from which the antibody was derived, or to the corresponding residue(s) in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one skilled in the art can readily produce numerous antibodies and antibody-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, the V H and / or V LAll framework and / or CDR residues within the domain are mutated back to the residue found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., the mutated residue is found within the first 8 amino acids of FR1, or the mutated residue is found within the last 8 amino acids of FR4, or the mutated residue is found only in CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and / or CDR residue(s) are mutated to the corresponding residue(s) in a different germline sequence (i.e., a germline sequence different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations in the framework and / or CDR regions, e.g., certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residue in a different germline sequence. Once obtained, antibodies and antibody binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonist or agonist biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antibody binding fragments obtained in this general manner are encompassed within the scope of the present invention.

[0058] The invention also includes fully human anti-FXII monoclonal antibodies comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the invention includes anti-FXII antibodies having HCVR, LCVR, and / or CDR amino acid sequences with, e.g., 10 or less, 8 or less, 6 or less, or 4 or less conservative amino acid substitutions relative to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein.

[0059] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human mAbs of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or by in vivo somatic mutation), for example in the CDRs, particularly CDR3. However, the term "human antibody" as used herein is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) are grafted onto human FR sequences. The term includes antibodies recombinantly produced in non-human mammals or cells of non-human mammals. The term is not intended to include antibodies isolated from or generated in a human subject.

[0060] The term "recombinant" as used herein refers to an antibody or antigen-binding fragment thereof of the present invention that is produced, expressed, isolated or obtained by techniques or methods known in the art as recombinant DNA technology, including, for example, DNA splicing and transgenic expression. The term refers to an antibody expressed in a non-human mammal (including a transgenic non-human mammal, e.g., a transgenic mouse), or cell (e.g., a CHO cell) expression system, or an antibody isolated from a recombinant combinatorial human antibody library.

[0061] Terms such as "specifically binds" or "binds specifically to" mean that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiological conditions. Specific binding is at least about 1×10 -8 M or less (e.g., a smaller K Dindicates tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. As described herein, antibodies that specifically bind to FXII have been identified by surface plasmon resonance, e.g., BIACORE™. Moreover, as used herein, multispecific antibodies that bind to one domain of FXII and one or more additional antigens, or bispecific antibodies that bind to two different regions of FXII, are nevertheless considered to be "specifically binding" antibodies.

[0062] The term "high affinity" antibody refers to D The binding affinity for FXII, expressed as -8 M, preferably 10 -9 M, more preferably 10 -10 M, and even more preferably 10 -11 M is measured by surface plasmon resonance, e.g., BIACORE™, or solution affinity ELISA.

[0063] The term "slow off rate", "Koff" or "kd" refers to a slow off rate of 1×10 as determined by surface plasmon resonance, e.g., BIACORE™. -3 s -1 Less than or equal to 1×10 -4 s -1 This means an antibody that dissociates from FXII with the following rate constant:

[0064] An "antigen-binding portion" of an antibody, an "antigen-binding fragment" of an antibody, and similar terms, as used herein, include naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptides or glycoproteins that specifically bind an antigen to form a complex. As used herein, the term "antigen-binding fragment" of an antibody, or simply "antibody fragment," refers to one or more fragments of an antibody that retain the ability to bind to an FXII protein.

[0065] In certain embodiments, the antibodies or antibody fragments of the present invention may be conjugated to a moiety such as a ligand or therapeutic moiety (an "immunoconjugate"), a second anti-FXII antibody, or any other therapeutic moiety useful for treating an FXII-associated disease or disorder.

[0066] As used herein, an "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies (Abs) having different antigen specificities (e.g., an isolated antibody that specifically binds to FXII and / or FXIIa, or a fragment thereof, is substantially free of Abs that specifically bind to antigens other than FXII or FXIIa.

[0067] As used herein, a "blocking antibody" or "neutralizing antibody" (or an "antibody that neutralizes FXII activity" or an "antagonist antibody") is intended to refer to an antibody whose binding to FXII / FXIIa results in inhibition of at least one biological activity of FXII. For example, an antibody of the present invention may prevent or block coagulation by the intrinsic pathway.

[0068] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows analysis of real-time biomolecular interactions through detection of changes in protein concentration within a biosensor matrix, for example, using the BIACORE™ system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ).

[0069] "K D The term "as used herein" is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.

[0070] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule, known as the paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different regions on an antigen and have different biological effects. The term "epitope" refers to a site on an antigen to which B cells and / or T cells respond. It also refers to the region of an antigen to which an antibody binds. Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes, and have residues that directly contribute to the affinity of the interaction. Epitopes may be conformational, i.e., composed of non-linear amino acids. In certain embodiments, epitopes may include determinants that are chemically active surface groupings of molecules, such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural and / or specific charge characteristics.

[0071] As used herein, the term "cross-compete" means that an antibody or antigen-binding fragment thereof binds to an antigen and inhibits or blocks the binding of another antibody or antigen-binding fragment thereof. The term also includes competition between two antibodies in both orientations, i.e., a first antibody that binds to a second antibody and blocks the binding of the second antibody, and vice versa. In certain embodiments, the first antibody and the second antibody may bind to the same epitope. Alternatively, the first antibody and the second antibody may bind to different but overlapping epitopes, such that the binding of one inhibits or blocks the binding of the second antibody, for example, through steric hindrance. Cross-competition between antibodies can be measured by methods known in the art, for example, by real-time label-free biolayer interferometry assays. Cross-competition between two antibodies can be expressed as the binding of the second antibody being lower than the background signal due to self-binding (in which case the first and second antibodies are the same antibody). Cross-competition between two antibodies can be expressed, for example, as the % binding of a second antibody below the baseline self-background binding (in this case, the first and second antibodies are the same antibody).

[0072] The term "substantial identity" or "substantially identical," when referring to a nucleic acid or a fragment thereof, indicates that when optimally aligned with another nucleic acid (or its complementary strand) with appropriate nucleotide insertions or deletions, there is at least about 90%, more preferably at least about 95%, about 96%, 97%, 98%, or 99% nucleotide sequence identity of the nucleotide bases as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST, or GAP, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule can, in certain cases, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0073] As applied to polypeptides, the term "substantial similarity" or "substantially similar" means that two peptide sequences share at least 90% sequence identity, and even more preferably at least 95%, 98% or 99% sequence identity, when optimally aligned, such as by the programs GAP or BESTFIT, using predefined gap weights. Preferably, non-identical residue positions differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions are not expected to substantially alter the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percentage or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24:307-331, incorporated herein by reference. Examples of amino acid groups having side chains with similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine, 2) aliphatic-hydroxyl side chains: serine and threonine, 3) amide-containing side chains: asparagine and glutamine, 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan, 5) basic side chains: lysine, arginine, and histidine, 6) acidic side chains: aspartic acid and glutamic acid, and 7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443 45, incorporated herein by reference. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0074] Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software uses similarity measurements assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions, to match similar sequences. For example, GCG software contains programs such as GAP and BESTFIT that can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms, or between wild-type protein and its mutant protein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and percent sequence identity of the region of best overlap between the query sequence and the search sequence (Pearson (2000) supra). Another preferred algorithm for comparing the sequences of the present invention to a database containing a large number of sequences from different organisms is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is incorporated herein by reference.

[0075] The phrase "therapeutically effective amount" means an amount that produces the desired effect for which it is administered. The exact amount will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0076] As used herein, the term "subject" refers to an animal, preferably a mammal, more preferably a human, in need of amelioration, prevention, and / or treatment of a FXII-related disease or disorder, such as thrombosis or embolism. The term includes human subjects having or at risk for such a disease or disorder.

[0077] As used herein, the terms "treat", "treating" or "treatment" refer to reducing or ameliorating the severity of at least one symptom or sign of a FXII-related disease or disorder by administering a therapeutic agent, such as an antibody of the present invention, to a subject in need thereof. These terms include inhibiting progression of the disease or worsening of symptoms / signs. The terms also include favorable prognosis of the disease, i.e., the subject may be disease-free or have reduced disease upon administration of a therapeutic agent, such as an antibody of the present invention. The therapeutic agent may be administered to the subject in a therapeutic dose.

[0078] The terms "prevent", "preventing" or "prevention" refer to the inhibition of the onset of a FXII-related disease or disorder, or any symptoms or signs of such a disease or disorder, upon administration of an antibody of the invention.

[0079] Antigen-binding fragment of an antibody Unless otherwise specified, the term "antibody" as used herein should be understood to encompass an antibody molecule comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., a "complete antibody molecule"), as well as antigen-binding fragments thereof. An "antigen-binding portion" of an antibody, an "antigen-binding fragment" of an antibody, and similar terms, as used herein, include naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptides or glycoproteins that specifically bind an antigen to form a complex. The term "antigen-binding fragment" of an antibody or "antibody fragment" as used herein refers to one or more fragments of an antibody that retain the ability to specifically bind to FXII protein. Antibody fragments include Fab fragments, F(ab') ... 2The term "antigen-binding fragment" may include a fragment, an Fv fragment, a dAb fragment, a fragment containing a CDR, or an isolated CDR. In certain embodiments, the term "antigen-binding fragment" refers to a polypeptide fragment of a multispecific antigen-binding molecule. Antigen-binding fragments of antibodies may be derived from complete antibody molecules using any suitable standard techniques, such as, for example, proteolytic or recombinant genetic engineering techniques, which involve the manipulation and expression of DNA encoding antibody variable and (optionally) constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated, for example, chemically or by using molecular biology techniques, to place one or more variable and / or constant domains into a suitable configuration, or to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids, etc.

[0080] Non-limiting examples of antigen-binding fragments include (i) Fab fragments, (ii) F(ab')2 fragments, (iii) Fd fragments, (iv) Fv fragments, (v) single chain Fv (scFv) molecules, (vi) dAb fragments, and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions (e.g., isolated complementarity determining regions (CDRs), such as CDR3 peptides) of an antibody, or constrained FR3-CDR3-FR4 peptides. Domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains are also encompassed by the term "antigen-binding fragment" as used herein.

[0081] An antigen-binding fragment of an antibody will typically contain at least one variable domain. A variable domain may be of any size or amino acid composition and generally contains at least one CDR adjacent to or in frame with one or more framework sequences. L V bound to the domain H In an antibody-binding fragment having a domain, H Domains and V L The domains can be arranged relative to each other in any suitable configuration. For example, the variable region is a dimer and the V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may contain a monomeric V H Domain or V L It may include a domain.

[0082] In certain embodiments, an antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody of the invention include: (i) a V H -C H 1, (ii) V H -C H 2. (iii) V H -C H 3. (iv) V H -C H 1-C H 2. (v) V H -C H 1-C H 2-C H 3. (vi) V H -C H 2-C H 3. (vii) V H -C L , (viii) V L -C H 1, (ix) V L -C H 2. (x)V L -CH 3. (xi) V L -C H 1-C H 2. (xii) V L -C H 1-C H 2-C H 3. (xiii) V L -C H 2-C H 3, and (xiv) V L -C L In any configuration of the variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible connection between adjacent variable and / or constant domains in a single polypeptide molecule. Moreover, antigen-binding fragments of the antibodies of the present invention may be linked to each other and / or to one or more monomeric V H Domain or V L The domains may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in non-covalent association (e.g., by disulfide bond(s)).

[0083] As with intact antibody molecules, antigen-binding fragments can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies typically contain at least two different variable domains, each capable of specifically binding to a separate antigen or a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in the context of the antigen-binding fragments of antibodies of the present invention using routine techniques available in the art.

[0084] Preparation of human antibodies Methods for generating human antibodies in transgenic mice are known in the art. Any such known method can be used in the context of the present invention to generate human antibodies that specifically bind to FXII and / or FXIIa.

[0085] To generate antibodies that specifically bind to FXII and / or FXIIa proteins, immunogens comprising any one of the following can be used. In certain embodiments, antibodies of the invention are obtained from mice immunized with full-length native FXII or FXIIa protein (see, e.g., UniProtKB / Swiss-Prot Accession No. P00748.3) or with DNA encoding the protein or a fragment thereof. Alternatively, the protein or a fragment thereof can be generated, modified, and used as an immunogen using standard biochemical techniques.

[0086] In some embodiments, the immunogen may be a recombinant FXII protein or a fragment thereof, expressed in E. coli or in any other eukaryotic or mammalian cell, such as Chinese Hamster Ovary (CHO) cells.

[0087] Using VELOCIMMUNE® technology (see, e.g., US 6,596,541, Regeneron Pharmaceuticals, VELOCIMUNE®) or any other known method for generating monoclonal antibodies, a high affinity chimeric antibody against FXII is first isolated, having a human variable region and a mouse constant region. VELOCIMMUNE® technology involves the generation of a transgenic mouse whose genome is operably linked to an endogenous mouse constant region locus, comprising a human heavy chain variable region and a human light chain variable region, such that the mouse produces an antibody comprising the human variable region and the mouse constant region in response to antigenic stimulation. DNA encoding the variable regions of the antibody heavy and light chains is isolated and operably linked to DNA encoding the human heavy chain constant region and the human light chain constant region. The DNA is then expressed in a cell capable of expressing a fully human antibody.

[0088] In general, VELOCIMMUNE® mice are loaded with an antigen of interest, and lymphocytes (such as B cells) are collected from the mice that express antibodies. Lymphocytes can be fused with myeloma cell lines to prepare immortalized hybridoma cell lines, which are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. DNA encoding the variable regions of the heavy and light chains can be isolated and linked to the desired isotype constant regions of the heavy and light chains. Such antibody proteins can be produced in cells such as CHO cells. Alternatively, DNA encoding the antigen-specific chimeric antibody or the variable domains of the light and heavy chains can be directly isolated from antigen-specific lymphocytes.

[0089] First, a high affinity chimeric antibody having a human variable region and a mouse constant region is isolated. As in the experimental section below, the antibody is characterized and selected for desirable characteristics including affinity, selectivity, epitope, etc. The mouse constant region is replaced with the desired human constant region to generate a fully human antibody of the present invention, e.g., wild-type or modified IgG1 or IgG4. Although the constant region selected can vary depending on the specific application, the high affinity antigen binding characteristics and target specificity characteristics reside in the variable region.

[0090] biological equivalent The anti-FXII antibodies and antibody fragments of the present invention encompass proteins having amino acid sequences that differ from those of the described antibodies but that retain the ability to bind to FXII protein. Such variant antibodies contain one or more additions, deletions, or substitutions of amino acids compared to the parent sequence, but exhibit biological activity that is essentially equivalent to that of the described antibodies. Similarly, DNA sequences encoding the antibodies of the present invention contain one or more additions, deletions, or substitutions of nucleotides compared to the disclosed sequences, but encode antibodies or antibody fragments that are essentially biologically equivalent to the antibodies or antibody fragments of the present invention.

[0091] Two antigen-binding proteins or antibodies are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical alternatives that do not show significant differences in absorption rate and extent when administered at the same molar dose, either in single or multiple doses, under similar experimental conditions. Some antibodies are to be considered equivalent or pharmaceutical alternatives if their absorption extent is equivalent but their absorption rate is not equivalent, and such differences in absorption rate are intentional and reflected in the labeling and therefore can be considered bioequivalent, e.g., are not essential to achieve effective body drug concentrations for long-term use and are not medically significant for the particular drug product studied.

[0092] In one embodiment, two antigen binding proteins are bioequivalent if there are no clinically significant differences in their safety, purity, or efficacy.

[0093] In one embodiment, two antigen binding proteins are bioequivalent if a patient can be switched one or more times compared to therapy sustained without switching between the reference product and the biological product without an expected increase in risk of adverse effects, including clinically significant changes in immunogenicity or reduced efficacy.

[0094] In one embodiment, two antigen binding proteins are biologically equivalent if they both act by a common mechanism or mechanism of action for the condition(s) of use, to the extent that such mechanism is known.

[0095] Bioequivalence may be demonstrated by in vivo and / or in vitro methods. Bioequivalence measurements include, for example, (a) in vivo studies in humans or other mammals in which the concentration of the antibody or its metabolites is measured as a function of time in blood, plasma, serum or other biological fluids, (b) in vitro studies that correlate with and are reasonably predictive of human bioavailability data, (c) in vivo studies in humans or other mammals in which the relevant acute pharmacological effects of the antibody (or its target) are measured as a function of time, and (d) well-controlled clinical trials that establish the safety, efficacy, or bioavailability or bioequivalence of the antibody.

[0096] Biologically equivalent variants of the antibodies of the present invention can be constructed, for example, by making various substitutions of residues or sequences, or by deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine ​​residues that are not essential for biological activity can be deleted or replaced with other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges during renaturation. In other contexts, biologically equivalent antibodies include antibody variants and can include amino acid changes that modify the glycosylation characteristic of antibodies, for example, mutations that eliminate or remove glycosylation.

[0097] Anti-FXII antibodies, including Fc variants According to certain embodiments of the invention, anti-FXII antibodies are provided that include an Fc domain that includes one or more mutations that enhance or decrease antibody binding to the FcRn receptor, e.g., at acidic pH compared to neutral pH. For example, the invention provides an anti-FXII antibody that includes an Fc domain that includes one or more mutations that enhance or decrease antibody binding to the FcRn receptor, e.g., at acidic pH compared to neutral pH. H 2 or C HThe present invention includes an anti-FXII antibody that includes a mutation in region 3, where the mutation(s) increase the affinity of the Fc domain for FcRn in an acidic environment (e.g., within an endosome where the pH ranges from about 5.5 to about 6.0). Such mutations can result in an increased serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q), 250 and 428 (e.g., L or F), 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T), or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., A, W, H, F, or Y [N434A, N434W, N434H, N434F, or N434Y]), or modifications at positions 250 and / or 428, or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications include 428L (e.g., M428L) and 434S (e.g., N434S) modifications, 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications, 433K (e.g., H433K) and 434 (e.g., 434Y) modifications, 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications, 250Q and 428L modifications (e.g., T250Q and M428L), 307 and / or 308 modifications (e.g., 308F or 308P). In yet another embodiment, the modifications include 265A (e.g., D265A) and / or 297A (e.g., N297A) modifications.

[0098] For example, the invention includes anti-FXII antibodies comprising an Fc domain containing one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 376V and 434H (e.g., D376V and N434H); 307A, 380A and 434A (e.g., T307A, E380A and N434A); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the aforementioned Fc domain mutations, as well as other mutations in the antibody variable domains disclosed herein, are contemplated within the scope of the present invention.

[0099] The present invention also relates to chimeric heavy chain constant (C H ) region, and H The region is composed of C H For example, the antibodies of the present invention may comprise a segment derived from a C region derived from a human IgG1 molecule, a human IgG2 molecule, or a human IgG4 molecule. H C derived from a human IgG1 molecule, a human IgG2 molecule, or a human IgG4 molecule, combined with some or all of the three domains. H Chimeric C containing part or all of the 2 domains H According to a particular embodiment, the antibody of the present invention may comprise a chimeric C region having a chimeric hinge region. HFor example, the chimeric hinge may comprise an "upper hinge" amino acid sequence (amino acid residues at positions 216-227 according to EU numbering) derived from a human IgG1, IgG2, or IgG4 hinge region combined with a "lower hinge" sequence (amino acid residues at positions 228-236 according to EU numbering) derived from a human IgG1, IgG2, or IgG4 hinge region. According to certain embodiments, the chimeric hinge region comprises amino acid residues derived from a human IgG1 or human IgG4 upper hinge and amino acid residues derived from a human IgG2 lower hinge. Chimeric C as described herein may be H Antibodies comprising the region may, in certain embodiments, exhibit modified Fc effector functions without adversely affecting the therapeutic or pharmacokinetic properties of the antibody (see, e.g., U.S. Patent Application Publication No. 2014 / 0243504, which is incorporated herein by reference in its entirety).

[0100] Biological properties of antibodies In general, the antibodies of the invention function by binding to the FXII protein and preventing its cleavage into FXIIa and FXIIb. In certain embodiments, the antibodies bind to the activated form of factor XII (FXIIa) ("dual FXII / FXIIa binders"). For example, the invention provides antibodies that bind to the activated form of factor XII (FXIIa) ("dual FXII / FXIIa binders") with a K of less than about 20 nM (e.g., at 25° C. or 37° C.) as measured using surface plasmon resonance, e.g., the assay format defined in Example 3 herein. D In certain embodiments, the antibody or antigen-binding fragment thereof has a K of less than about 20 nM, less than about 17 nM, less than about 10 nM, less than about 5 nM, or less than about 1 nM, as measured by surface plasmon resonance, e.g., using the assay format defined in Example 3 herein, or a substantially similar assay. D and binds to FXII.

[0101] The present invention also includes antibodies and antigen-binding fragments thereof that bind to human FXII protein with a dissociation half-life (t1 / 2) of greater than about 1 minute, e.g., as measured by surface plasmon resonance at 25° C. or 37° C. using the assay format defined in Example 3 herein, or a substantially similar assay. In certain embodiments, antibodies or antigen-binding fragments of the present invention bind to FXII protein with a t1 / 2 of greater than about 5 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, or greater than about 70 minutes, e.g., as measured by surface plasmon resonance at 25° C. or 37° C. using the assay format defined in Example 3 herein, or a substantially similar assay.

[0102] The present invention includes antibodies and antigen-binding fragments of antibodies, having a K of less than about 9 nM (e.g., at 25° C. or 37° C.), as measured by surface plasmon resonance, e.g., using the assay format defined in Example 3 herein. D In certain embodiments, the antibody or antigen-binding fragment thereof has a K of less than about 9 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 500 pM, as measured by surface plasmon resonance, e.g., using the assay format defined in Example 3 herein, or a substantially similar assay. D and binds to FXIIa.

[0103] The present invention also includes antibodies and antigen-binding fragments thereof that bind to human FXIIa protein with a dissociation half-life (t1 / 2) of greater than about 1 minute, e.g., as measured by surface plasmon resonance at 25° C. or 37° C. using the assay format defined in Example 3 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments of the present invention bind to FXIIa protein with a t1 / 2 of greater than about 5 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, or greater than about 70 minutes, e.g., as measured by surface plasmon resonance at 25° C. or 37° C. using the assay format defined in Example 3 herein, or a substantially similar assay.

[0104] The invention also includes antibodies and antigen-binding fragments thereof that inhibit thrombin generation via the intrinsic pathway at concentrations of less than 250 nM, less than 200 nM, or less than 150 nM, e.g., as measured using the assay format described in Example 5 herein, or a substantially similar assay. In certain embodiments, the invention includes antibodies and antigen-binding fragments thereof that inhibit thrombin generation via the intrinsic pathway without blocking thrombin generation via the extrinsic pathway, e.g., as measured using the assay format described in Example 5 herein, or a substantially similar assay.

[0105] In one embodiment, the present invention provides an isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to FXII protein, wherein the antibody or fragment thereof exhibits one or more of the following characteristics: (a) is a fully human monoclonal antibody; (b) binds to activated factor XII (FXIIa); and (c) has a dissociation constant (K) of less than 3.5 nM at 25° C. as measured in a surface plasmon resonance assay. D ) and binds to FXII; (d) has a K of less than 17 nM at 37° C. as measured in a surface plasmon resonance assay. D and binds to FXII at 25° C. with a K of less than 5 nM, preferably less than 2.5 nM, as measured in a surface plasmon resonance assay. D (f) a K of less than 6.5 nM, preferably less than 2.5 nM, at 37° C., as measured in a surface plasmon resonance assay. D (g) blocks thrombin generation by the intrinsic pathway at concentrations less than 250 nM, as measured by a functional plasma assay; and (h) blocks thrombin generation by the intrinsic pathway without blocking thrombin generation by the extrinsic pathway, as measured by a functional plasma assay.

[0106] The antibodies of the invention may have one or more of the aforementioned biological properties, or any combination thereof. Other biological properties of the antibodies of the invention will be apparent to those of skill in the art from a review of this disclosure, including the Examples herein.

[0107] Epitope mapping and related techniques The present invention includes anti-FXII / FXIIa antibodies that interact with one or more amino acids found within one or more regions of the FXII / FXIIa protein molecule, including the heavy and light chains. The epitope to which the antibody binds may consist of a single contiguous sequence of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) amino acids located in any of the aforementioned domains of the FXII protein molecule (e.g., a linear epitope of a domain). Alternatively, the epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) located in either or both of the aforementioned domains of the protein molecule (e.g., a conformational epitope).

[0108] Various techniques known to those skilled in the art can be used to determine whether an antibody "interacts with one or more amino acids" within a polypeptide or protein. Exemplary techniques include the conventional cross-blocking assay described, for example, in Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY). Other methods include alanine scanning mutation analysis, peptide blot analysis (Reineke (2004) Methods Mol. Biol. 248:443-63), peptide truncation analysis, crystallographic studies, and NMR analysis. In addition, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be used (Tomer (2000) Prot. Sci. 9:487-496). Another method that can be used to identify the amino acids within a polypeptide that an antibody interacts with is hydrogen / deuterium exchange, detected by mass spectrometry. Generally speaking, hydrogen / deuterium exchange involves deuterium labeling of the protein of interest, followed by binding of the antibody to the deuterium-labeled protein. The protein / antibody complex is then transferred to water, and exchangeable protons in amino acids protected by the antibody complex undergo deuterium-to-hydrogen back-exchange at a slower rate than exchangeable protons in amino acids that are not part of the interface. As a result, amino acids that form part of the protein / antibody interface can retain deuterium and therefore exhibit a relatively larger mass compared to amino acids that are not included in the interface. After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry, thereby revealing deuterium-labeled residues that correspond to the specific amino acids with which the antibody interacts. See, for example, Ehring (1999) Analytical Biochemistry 267:252-259; Engen and Smith (2001) Anal.Chem.73:256A-265A.

[0109] The term "epitope" refers to a site on an antigen to which B cells and / or T cells respond. B cell epitopes can be formed both from contiguous amino acids, or from non-contiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. Epitopes typically contain at least 3, more commonly at least 5, or 8-10 amino acids in a unique spatial conformation.

[0110] Modification-Assisted Profiling (MAP), also known as Structure-based Antibody Profiling (ASAP), is a method for classifying a large number of monoclonal antibodies (mAbs) directed against the same antigen according to the similarity of the binding profile of each antibody to a chemically or enzymatically modified antigen surface (see US 2004 / 0101920, specifically incorporated herein by reference in its entirety). Each category may reflect a unique epitope that is clearly distinct or partially overlapping with the epitopes represented by another category. This technique allows for rapid filtering of genetically identical antibodies so that characterization can be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP can facilitate the identification of rare hybridoma clones that produce mAbs with desired characteristics. MAP can be used to sort the antibodies of the invention into groups of antibodies that bind to different epitopes.

[0111] In certain embodiments, the present invention includes anti-FXII antibodies and antigen-binding fragments thereof that interact with one or more epitopes found within the heavy and / or light chains of FXIIa. The epitope(s) may consist of one or more contiguous sequences of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) amino acids located within the heavy and / or light chains of FXIIa. Alternatively, the epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) located within FXIIa.

[0112] The present invention includes anti-FXII antibodies that bind to the same epitope or portion of an epitope as any of the specific exemplary antibodies listed in Table 1. Similarly, the present invention also includes anti-FXII antibodies that compete for binding to FXII protein or fragments thereof with any of the specific exemplary antibodies listed in Table 1. For example, the present invention includes anti-FXII antibodies that cross-compete with one or more of the antibodies listed in Table 1 for binding to FXII protein.

[0113] Whether an antibody binds to the same epitope as a reference anti-FXII antibody or competes with a reference anti-FXII antibody for binding to an epitope can be easily determined by using conventional methods known in the art. For example, to determine whether a test antibody binds to the same epitope as a reference anti-FXII antibody of the present invention, the reference antibody is bound to an FXII protein or peptide under saturating conditions. The ability of the test antibody to bind to an FXII protein molecule is then evaluated. If the test antibody can bind to FXII after saturation binding with the reference anti-FXII antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-FXII antibody. On the other hand, if the test antibody cannot bind to FXII after saturation binding with the reference anti-FXII antibody, the test antibody may bind to the same epitope as the epitope bound by the reference anti-FXII antibody of the present invention.

[0114] To determine whether an antibody competes with a reference anti-FXII antibody for binding, the binding method described above is carried out in two directions. In the first direction, the reference antibody is allowed to bind to FXII protein under saturating conditions, and then the binding of the test antibody to the FXII molecule is evaluated. In the second direction, the test antibody is allowed to bind to FXII protein under saturating conditions, and then the binding of the reference antibody to the FXII molecule is evaluated. If the first (saturating) antibody can bind to the FXII molecule in both directions, it is concluded that the test antibody and the reference antibody compete for binding to FXII. As will be understood by those skilled in the art, an antibody that competes with a reference antibody for binding does not necessarily have to bind to the same epitope as the reference antibody, but may sterically block the binding of the reference antibody by binding to an overlapping or adjacent epitope.

[0115] Two antibodies bind to the same or overlapping epitopes if each competitively inhibits (blocks) the other from binding to the antigen. That is, a 1-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antibody inhibits the binding of the other by at least 50%, but preferably 75%, 90%, or even 99%, as measured by competitive binding assays (see, for example, Junghans et al., Cancer Res. 1990 50:1495-1502). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations of the antigen that reduce or eliminate the binding of one antibody reduce or eliminate the binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate the binding of one antibody reduce or eliminate the binding of the other.

[0116] Further routine experiments (e.g., peptide mutations and binding analysis) can then be performed to confirm whether the observed loss of binding of the test antibody is indeed due to binding to the same epitope as the reference antibody, or whether steric blocking (or another phenomenon) is responsible for the observed loss of binding. This type of experiment can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art.

[0117] immunoconjugate The present invention encompasses human anti-FXII monoclonal antibodies conjugated to a therapeutic moiety ("immunoconjugate") for treating FXII-related diseases or disorders (e.g., thrombosis). As used herein, the term "immunoconjugate" refers to an antibody chemically or biologically linked to a radioactive agent, cytokine, interferon, target or reporter moiety, enzyme, peptide or protein, or therapeutic agent. The antibody may be linked to a radioactive agent, cytokine, interferon, target or reporter moiety, enzyme, peptide, or therapeutic agent at any position along the molecule, so long as it is capable of binding to its target. Examples of immunoconjugates include antibody drug conjugates and antibody-toxin fusion proteins. In one embodiment, the agent may be a second, different antibody against the FXII protein. The type of therapeutic moiety that may be conjugated to the anti-FXII antibody takes into account the condition to be treated and the desired therapeutic effect to be achieved. Examples of agents suitable for forming immunoconjugates are known in the art (see, for example, WO05 / 103081).

[0118] multispecific antibody The antibody of the present invention can be monospecific, bispecific or multispecific.Multispecific antibodies can be specific to different epitopes of one target polypeptide, or can contain antigen binding domains specific to two or more target polypeptides.See, for example, Tutt et al., 1991, J.Immunol.147:60-69; Kufer et al., 2004, Trends Biotechnol.22:238-244.

[0119] Any of the multispecific antigen-binding molecules of the present invention, or variants thereof, can be constructed using standard molecular biology techniques (e.g., recombinant DNA and protein expression techniques), as known to those skilled in the art.

[0120] In some embodiments, FXII-specific antibodies are produced in a bispecific format ("bispecific") in which variable regions that bind different domains of the FXII protein are linked together to confer dual domain specificity in a single binding molecule. Properly designed bispecifics can enhance overall FXII-protein inhibitory efficacy through increasing both specificity and avidity. Variable regions with specificity for individual domains (e.g., segments of the N-terminal domain) or variable regions that can bind to different regions within one domain are paired on a structural scaffold that allows each region to simultaneously bind to a distinct epitope or to different regions within one domain. Bispecific heavy chain variable regions (VHV ... H In one example, a light chain variable region (V) from a series of binders with specificity for a second domain is L ) and V H without destroying the original singularity for the original V H A non-cognate V that can pair with L Identify the partner. In this way, a single V L Segment (e.g., V L 1) Two different V H Domain (e.g., V H 1 and V H2) to form two binding "arms" (V H 1-V L 1 and V H 2-V L 1) can be used to generate bispecific antibodies consisting of a single V L The use of segments reduces the complexity of the system, thereby simplifying and increasing the efficiency of the cloning, expression, and purification processes used to generate bispecifics (see, e.g., USSN13 / 022759 and US2010 / 031527).

[0121] Alternatively, antibodies that bind to two or more domains and a second target (such as, but not limited to, a second, different anti-FXII antibody) can be prepared in a bispecific format using the techniques described herein or other techniques known to those of skill in the art. Antibody variable regions that bind to different regions can be linked together, for example, with a variable region that binds to a related site on the extracellular domain of FXII to confer dual antigen specificity within a single binding molecule. A properly designed bispecific of this nature serves a dual function. A variable region with specificity for the extracellular domain is combined with a variable region with specificity for a non-extracellular domain, paired on a structural scaffold that allows each variable region to bind a separate antigen.

[0122] An exemplary bispecific antibody format that can be used in the context of the present invention is H 3 domain and second IgC H 3 domain usage, and the first and second IgC H The three domains differ from each other by at least one amino acid, and the at least one amino acid difference reduces binding of the bispecific antibody to Protein A compared to a bispecific antibody lacking the amino acid difference. H The 3 domain binds protein A and is a second IgC H The C3 domain contains a mutation that reduces or abolishes Protein A binding, such as the H95R modification (according to IMGT exon numbering, H435R in EU numbering).H 3 may further comprise a Y96F modification (according to IMGT and Y436F in EU). H Additional modifications that may be found within 3 include D16E, L18M, N44S, K52N, V57M, and V82I for IgG1 antibodies (D356E, L358M, N384S, K392N, V397M, and V422I according to IMGT, EU), N44S, K52N, and V82I for IgG2 antibodies (N384S, K392N, and V422I according to IMGT, EU), and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I for IgG4 antibodies (Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I according to IMGT, EU). Variations on the bispecific antibody formats described above are contemplated as being within the scope of the present invention.

[0123] Other exemplary bispecific formats that may be used in the context of the present invention include, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadromas, knobs-into-holes, common light chains (e.g., common light chains with knobs-into-holes), CrossMab, CrossFab, (SEED) bodies, leucine zippers, Duobodies, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab 2 These include, but are not limited to, bispecific formats (for a review of the above formats, see, e.g., Klein et al. 2012, mAbs 4:6,1-11 and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid linkages, e.g., using unnatural amino acids with orthogonal chemical reactivity to generate site-specific antibody-oligonucleotide conjugates that then self-assemble into multimeric complexes with defined composition, valency and geometry. (See, e.g., Kazane et al., J. Am. Chem. Soc. [Epub: Dec. 4, 2012]).

[0124] Therapeutic Administration and Formulations The present invention provides therapeutic compositions comprising the anti-FXII antibody or antigen-binding fragment thereof of the present invention. The therapeutic compositions according to the present invention are administered with suitable carriers, excipients, and other agents incorporated into the formulation, resulting in improved entry, delivery, tolerance, and the like. A large number of suitable formulations can be found in formularies known to any pharmaceutical chemist: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.

[0125] The dose of the antibody may vary depending on the age and size of the subject to be administered, the target disease, condition, route of administration, etc. When the antibody of the present invention is used to treat a disease or disorder in an adult patient or to prevent such a disease, it is usually advantageous to administer the antibody of the present invention at a single dose of about 0.1 to about 100 mg / kg body weight. Depending on the severity of the condition, the frequency and duration of treatment can be adjusted. In certain embodiments, the antibody or antigen-binding fragment of the present invention may be administered at an initial dose of about 0.1 mg to about 800 mg, about 1 mg to about 600 mg, about 5 mg to about 500 mg, or about 10 mg to about 400 mg. In certain embodiments, the initial dose may be followed by a second or multiple subsequent doses of the antibody or antigen-binding fragment thereof, in an amount that is about the same as or less than the initial dose, or in an amount that may be about the same as or less than the initial dose, with the subsequent doses being at least 1 to 3 days apart, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 12 weeks, or at least 14 weeks apart.

[0126] Various delivery systems, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis, are known and can be used to administer the pharmaceutical compositions of the present invention (see, for example, Wu et al. (1987) J.Biol.Chem.262:4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral routes. The compositions can be administered by any convenient route, for example, by infusion or bolus injection, absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents. Administration can be systemic or local. The pharmaceutical compositions can also be delivered in vesicles, in particular liposomes (see, eg, Langer (1990) Science 249:1527-1533).

[0127] The use of nanoparticles to deliver the antibodies of the present invention is also contemplated herein. Antibody-conjugated nanoparticles can be used for both therapeutic and diagnostic applications. Antibody-conjugated nanoparticles and preparation and use methods are described in detail in Arruebo, M., 2009 ("Antibody-conjugated nanoparticles for biomedical applications" in J.Nanomat.Volume 2009,Article ID 439389,24 pages,doi:10.1155 / 2009 / 439389), which is incorporated herein by reference. Nanoparticles can be developed and conjugated to antibodies contained in pharmaceutical compositions to target cells. Nanoparticles for drug delivery are also described, for example, in US Patent No. US8257740, or US8246995, each of which is incorporated herein in its entirety.

[0128] In certain circumstances, the pharmaceutical composition can be delivered in a sustained release system. In one embodiment, a pump can be used. In another embodiment, a polymeric material can be used. In yet another embodiment, the sustained release system can be placed in the vicinity of the target of the composition, thus requiring only a fraction of the systemic dose.

[0129] The injectable preparations may include dosage forms for intravenous, subcutaneous, intracranial, intraperitoneal and intramuscular injections, infusion, etc. These injectable preparations may be prepared by publicly known methods.

[0130] The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously using a standard needle and syringe. In addition, for subcutaneous delivery, a pen delivery device has easy application in delivering the pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and easily replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device is pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is empty of the pharmaceutical composition, the entire device is discarded.

[0131] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into a suitable unit dose dosage form to suit the dose of the active ingredient. Such unit dose dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of antibody contained is generally about 5 to about 500 mg per unit dose dosage form, and particularly in the form of injection, it is preferable that the antibody is contained about 5 to about 300 mg, and for other dosage forms, it is preferable that the antibody is contained about 10 to about 300 mg.

[0132] Diagnostic Uses of Antibodies The antibodies of the invention are useful for the treatment and / or prevention of a disease or disorder or condition associated with coagulation (including thrombosis and embolism) or edema (e.g., hereditary angioedema) and / or for the amelioration of at least one symptom associated with such a disease, disorder or condition. In certain embodiments, the antibodies of the invention or antigen-binding fragments thereof may be administered in therapeutic doses to patients having a disease or disorder or condition associated with coagulation or edema. In certain embodiments, the antibodies of the invention or antigen-binding fragments thereof are administered to a subject in need thereof to prevent thrombosis without increasing the risk of bleeding.

[0133] In certain embodiments, the antibodies of the invention are useful for treating or preventing at least one symptom or sign of a FXII-related disease or disorder selected from the group consisting of venous thrombosis, arterial thrombosis, device thrombosis, thromboembolism, hereditary angioedema, stroke, thrombotic predisposition, cardiac ischemia, atherosclerotic plaque rupture, use of mechanical valve prostheses, use of blood-contacting medical devices, use of blood-contacting extracorporeal circuits, venous thromboembolism, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, Budd-Chiari syndrome, Paget-Schroetter disease, renal vein thrombosis, cerebral venous sinus thrombosis, jugular vein thrombosis, cavernous sinus thrombosis, hepatic artery thrombosis, lower limb ischemia, and myocardial infarction.

[0134] Also contemplated herein is the prophylactic use of one or more antibodies of the invention in subjects at risk for thrombosis, such as those using extracorporeal membrane oxygenation (cardiopulmonary bypass). The antibodies of the invention can be used to prevent thrombotic occlusion of the oxygenator and tubing in the extracorporeal circuit.

[0135] In a further embodiment of the invention, the antibody is used for the preparation of a pharmaceutical composition or medicament for treating a patient suffering from a disease, disorder or condition disclosed herein. In another embodiment of the invention, the antibody is used as an adjunct therapy with any other agent useful in the treatment or amelioration of a disease, disorder or condition disclosed herein or any other therapy known to one skilled in the art.

[0136] Combination therapy The combination therapy may include the antibody of the present invention and any additional therapeutic agent that may be advantageously combined with the antibody of the present invention or with a biologically active fragment of the antibody of the present invention. The antibody of the present invention may be synergistically combined with one or more drugs or therapies used to treat a disease or disorder associated with thrombosis, in particular to prevent thrombosis or to treat a subject at risk of thrombosis due to an underlying disease, disorder or condition (as described elsewhere herein). In some embodiments, the antibody of the present invention may be combined with a second therapeutic agent to ameliorate one or more symptoms of the disease or condition.

[0137] Depending on the disease, disorder or condition, the antibodies of the invention can be used in combination with one or more additional therapeutic agents, including, but not limited to, anticoagulants (e.g., warfarin, heparin, phenindione, fondaparinux, idraparinux), thrombin inhibitors (e.g., argatroban, lepirudin, bivalirudin, or dabigatran), thrombolytic agents, antiplatelet agents (e.g., aspirin), antihypertensive agents (e.g., angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers), immunosuppressants (e.g., vincristine, cyclosporine A, or methotrexate), fibrinolytic agents, cholesterol-lowering agents (e.g., statins or PCSK9 inhibitors, e.g., alirocumab), anti-inflammatory agents (e.g., corticosteroids, or nonsteroidal anti-inflammatory drugs), a second anti-FXII antibody, mechanical clot retrieval, catheter-directed thrombolysis, and surgery.

[0138] As used herein, the term "in combination with" means that an additional therapeutically active ingredient(s) may be administered prior to, simultaneously with, or after administration of the anti-FXII antibody of the present invention. The term "in combination with" also includes sequential or simultaneous administration of an anti-FXII antibody and a second therapeutic agent.

[0139] The additional therapeutically active ingredient(s) may be administered to the subject prior to administration of the anti-FXII antibody of the present invention. For example, if the first component is administered 1 week, 72 hours, 60 hours, 48 ​​hours, 36 hours, 24 hours, 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less than 30 minutes before administration of the second component, the first component may be considered to be administered "before" the second component. In other embodiments, the additional therapeutically active ingredient(s) may be administered to the subject after administration of the anti-FXII antibody of the present invention. For example, if the first component is administered 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, or more after administration of the second component, the first component may be considered to be administered "after" the second component. In yet other embodiments, the additional therapeutically active ingredient(s) may be administered to the subject simultaneously with administration of the anti-FXII antibody of the present invention. "Concurrent" administration, for purposes of the present invention, includes, for example, administering the anti-FXII antibody and the additional therapeutically active ingredient to the subject in a single dosage form, or administering the anti-FXII antibody and the additional therapeutically active ingredient to the subject in separate dosage forms within about 30 minutes or less of each other. When administered in separate dosage forms, each dosage form may be administered via the same route (e.g., both the anti-FXII antibody and the additional therapeutically active ingredient may be administered, such as intravenously). Alternatively, each dosage form may be administered via a different route (e.g., the anti-FXII antibody may be administered intravenously and the additional therapeutically active ingredient may be administered orally). In any event, for purposes of the present disclosure, administering the ingredients in different dosage forms by the same route, in a single dosage form, or by different routes and in different dosage forms are all considered "concurrent administration." For purposes of this disclosure, administration of an anti-FXII antibody "before," "concurrently with," or "after" administration of an additional therapeutically active ingredient (as those terms are defined herein above) will be considered administration of the anti-FXII antibody "in combination with" the additional therapeutically active ingredient.

[0140] The present invention includes pharmaceutical compositions in which an anti-FXII antibody of the present invention is co-formulated with one or more of the additional therapeutically active ingredient(s) described elsewhere herein.

[0141] Diagnostic Uses of Antibodies The antibodies of the invention may be used to detect and / or measure FXII in a sample, e.g., for diagnostic purposes. Some embodiments contemplate the use of one or more antibodies of the invention in an assay for detecting a FXII-associated disease or disorder. An exemplary diagnostic assay for FXII may, for example, include contacting a sample obtained from a patient with an anti-FXII antibody of the invention, which is labeled with a detectable label or reporter molecule or used as a capture ligand to selectively isolate FXII from the patient sample. Alternatively, an unlabeled anti-FXII antibody may be used for diagnostic applications in combination with a secondary antibody that is itself detectably labeled. The detectable label or reporter molecule may be 3 H, 14 C. 32 P, 35 S or 125 The FXII may be a radioisotope such as I, or a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate or rhodamine, or an enzyme such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure FXII in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS).

[0142] Samples that can be used in the FXII diagnostic assay according to the present invention include any tissue or body fluid sample that can be obtained from a patient that contains a detectable amount of FXII protein or a fragment thereof under normal or pathological conditions. In general, the level of FXII protein in a particular sample obtained from a healthy patient (e.g., a patient not suffering from a disease associated with FXII) will be measured to first establish a baseline or standard level of FXII. This baseline level of FXII can then be compared to the level of FXII measured in a sample obtained from an individual suspected of having a FXII-related condition or a symptom associated with that condition.

[0143] Antibodies specific for FXII protein may contain no additional labels or moieties, or they may contain N-terminal or C-terminal labels or moieties. In one embodiment, the label or moiety is biotin. In binding assays, the position of the label (if any) may determine the orientation of the peptide relative to the surface to which it binds. For example, if the surface is coated with avidin, a peptide containing an N-terminal biotin will be oriented such that the C-terminal portion of the peptide is distal to the surface. EXAMPLES

[0144] The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, room temperature is about 25°C, and pressure is at or near atmospheric pressure.

[0145] Example 1: Generation of human antibodies against factor XII / activated factor XII (FXII / FXIIa) protein Human antibodies against FXII / FXIIa proteins were generated in VELOCIMMUNE mice, which contain DNA encoding human immunoglobulin heavy chain and kappa light chain variable regions. Mice were immunized with plasma-purified human FXII and FXIIa proteins (Enzyme Research Laboratories).

[0146] Anti-FXII antibodies were isolated directly from antigen-positive mouse B cells without fusion to myeloma cells, as described in U.S. Patent No. 7,582,298, specifically incorporated herein by reference in its entirety. Using this method, several fully human anti-FXII antibodies (i.e., antibodies having human variable and human constant domains) were obtained, and exemplary antibodies generated in this manner were designated mAb26036, mAb26048, mAb26049, and mAb26076.

[0147] The biological properties of exemplary antibodies generated according to the methods of this Example are described in detail in the Examples set forth below.

[0148] Example 2: Amino acid and nucleic acid sequences of heavy and light chain variable regions Table 1 shows the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-FXII antibodies of the invention. [Table 1]

[0149] The corresponding nucleic acid sequence identifiers are shown in Table 2. [Table 2]

[0150] The antibodies referred to herein typically have fully human variable regions, but may have human or mouse constant regions. As will be appreciated by those skilled in the art, an antibody with a particular Fc isotype may be converted to an antibody with a different Fc isotype (e.g., an antibody with a mouse IgG1 Fc may be converted to an antibody with a human IgG4, etc.), but in any case, the variable domains (including the CDRs) indicated by the numerical identifiers shown in Table 2 remain the same, and the binding characteristics to the antigen are expected to be the same or substantially similar regardless of the nature of the Fc domain. In certain embodiments, a selected antibody with a mouse IgG1 Fc is converted to an antibody with a human IgG4 Fc. In one embodiment, the IgG4 Fc domain contains two or more amino acid changes disclosed in US Patent Application No. US2010 / 0331527. In one embodiment, the human IgG4 Fc contains a serine to proline mutation (S108P) in the hinge region to promote dimer stabilization.

[0151] Control constructs used in the following examples For comparison purposes, the following control constructs (anti-FXII antibodies) were included in the experiments disclosed herein: "Comparative 1" is the V-type construct of the antibody "3F7" according to U.S. Pat. No. 9,518,127 (CSL Behring GmbH). H / V L and "Comparative 2" is a monoclonal antibody against human FXII / FXIIa having the sequence VIII of the antibody "15H8" according to U.S. Pat. No. 9,574,013 (Vanderbilt Univ. / Aronora). H / V L It is a human monoclonal antibody against human FXII having the sequence

[0152] Example 3: Antibody binding to FXII as determined by surface plasmon resonance The equilibrium dissociation constants (K D) was determined using a real-time surface plasmon resonance-based Biacore4000 biosensor. All binding studies were performed at 25°C and 37°C in a running buffer of 10 mM HEPES, 300 mM NaCl, and 0.05% v / v detergent Tween-20, pH 7.4 (HBS-P). The surface of a Biacore CM5 sensor chip was first derivatized by amine coupling with a mouse anti-human Fc-specific monoclonal antibody (GE Healthcare, Cat# BR100839) to capture the anti-FXII monoclonal antibody. Binding studies were performed with human FXII and FXIIa (Enzyme Research Laboratories, Cat# 1212 and 1212a, respectively). Different concentrations of hFXII and hFXIIa (50 nM to 3.125 nM, 2-fold serial dilutions) were first prepared in HBS-P running buffer and injected over the surface of anti-human Fc-captured anti-FXII monoclonal antibody at a flow rate of 30 μL / min for 3 min, during which the dissociation of monoclonal antibody-bound FXII reagent was monitored for 5 min in HBS-P running buffer. The association rate (k a ) and dissociation rate (k d The binding dissociation equilibrium constant (K) was determined by fitting the real-time binding sensorgrams to a 1:1 binding model with mass transport limitation using Scrubber 2.0c curve fitting software. D ) and dissociation half-life (t1 / 2) were calculated from the kinetic rates as follows:

number

[0153] The binding kinetic parameters of hFXII or hFXIIa bound to different anti-hFXII monoclonal antibodies of the present invention at 25° C. and 37° C. are shown in Tables 3-6. [Table 3] [Table 4] [Table 5] [Table 6]

[0154] As shown in Table 3, the antibodies bound to hFXII with K values ​​ranging from 0.88 nM to 3.12 nM at 25° C. As shown in Table 4, the antibodies bound to hFXII with K values ​​ranging from 2.53 nM to 16.8 nM at 37° C.

[0155] As shown in Table 5, the antibodies bound to hFXIIa with K values ​​ranging from 0.61 nM to 5.07 nM at 25° C. As shown in Table 6, the antibodies bound to hFXIIa with K values ​​ranging from 1.79 nM to 8.25 nM at 37° C.

[0156] Example 4: Octet cross-competition assay Binding competition between a panel of anti-FXII monoclonal antibodies was determined using a real-time label-free biolayer interferometry assay on an Octet HTX biosensor (Pall ForteBio Corp.) Experiments were performed in 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 0.05% v / v surfactant Tween-20, 0.1 mg / mL BSA (Octet HBS-P buffer) at 25°C with plates shaking at a speed of 1000 rpm. To assess whether the two antibodies could compete with each other for binding to their respective epitopes on human FXII (ERL) in approximately 0.42-0.53 nM anti-human FXII monoclonal antibodies, antibodies were first captured on an anti-hFc antibody-coated Octet biosensor chip (Pall ForteBio Corp., #18-5060) by immersing the chip in a well containing 50 μg / mL of anti-human FXII monoclonal antibody (hereafter referred to as mAb-1) solution for 3 min. The biosensor chip with the captured antibody was then saturated with a control monoclonal antibody of the mAb isotype (hereafter referred to as blocking mAb) by immersing the chip in a well containing 200 μg / mL of blocking mAb solution for 4 min. The biosensor chip was then immersed in a well containing a co-complexed solution of 25 nM hFXII and 1 μM of a second anti-human FXII monoclonal antibody (hereafter referred to as mAb-2) that had been pre-incubated for 2 h. The biosensor chip was washed with octet HBS-P buffer between each step of the experiment. Real-time binding responses were monitored during the course of the experiment and recorded at the end of each step. The responses of mAb-2 precomplexed with human FXII binding to mAb-1 were corrected for background binding and compared to determine the competitive / noncompetitive behavior of the different anti-FXII monoclonal antibodies. [Table 7]

[0157] Table 7 explicitly defines the relationships of competing antibodies in both orientations, regardless of the order of binding.

[0158] Example 5: Functional plasma assay to determine the inhibitory activity of anti-FXII / FXIIa antibodies This example describes the inhibitory activity of selected antibodies, determined by four functional plasma assays: 1) activated partial thromboplastin time (aPTT), 2) prothrombin time (PT), 3) thrombin generation assay (TGA) induced by ellagic acid, and 4) TGA induced by tissue factor. The aPTT test evaluates all clotting factors of the intrinsic and common pathways of the coagulation cascade by measuring the time for a clot to form after the addition of calcium and ellagic acid, whereas the PT test evaluates all clotting factors of the extrinsic and common pathways of the coagulation cascade after the addition of calcium and tissue factor. The TGA induced by ellagic acid measures the rate and amount of thrombin generated via the intrinsic and common pathways, whereas the TGA induced by tissue factor measures the rate and amount of thrombin generated via the extrinsic and common pathways.

[0159] Measurement of aPTT aPTT was determined on a Diagnostica Stago STart4 hemostasis analyzer in the following manner: A total of 50 μL of pooled normal human plasma at 37° C. was added to a cuvette. After 1 min, 5 μL of 2-fold serially diluted test substances (antibodies or small molecule inhibitors) in PBS were added to the cuvette and allowed to incubate for 5 min. 50 μL of APPT-XL Ellagic Acid (Thermo Scientific) was then added and incubated for 300 s, after which 50 μL of 20 mM calcium chloride (Thermo Scientific) was added to initiate the reaction. Measured clotting times of test substance concentrations were normalized to baseline (drug-free) plasma clotting times and plotted against the log molar concentration of the test substance. Results were analyzed using nonlinear regression (4-parameter logistics) with Prism5 software (GraphPad) to obtain doubling time concentrations.

[0160] PT decision PT was determined on a Diagnostica Stago STart4 hemostatic analyzer in the following manner: A total of 50 μl of pooled normal human plasma at 37° C. was added to the cuvette. After 1 min, 5 μL of test substances (antibodies or small molecule inhibitors) serially diluted 2-fold in PBS were added to the cuvette and allowed to incubate for 5 min. The reaction was then initiated by the addition of 100 μl of tissue factor (TriniCLOT PT Excel, Diagnostica Stago). The measured clotting times of the test substance concentrations were normalized to baseline (drug-free) plasma clotting times and plotted against the log molar concentration of the test substance. Results were analyzed using nonlinear regression (4-parameter logistics) with Prism5 software (GraphPad) to obtain doubling time concentrations.

[0161] TGA determination with ellagic acid Thrombin generation profiles were determined on a Thermo Scientific Hemker Thrombinoscope in the following manner: A total of 55ul of pooled normal human plasma was added to the wells of a microplate at 37°C. 5ul of two-fold serially diluted test substances (antibodies or small molecule inhibitors) in PBS were then added to the wells of the microplate and allowed to incubate for 30 minutes. 15ul of APPT-XL Ellagic Acid (Thermo Scientific) was diluted in MP Reagent and then added to the wells and allowed to incubate for 45 minutes. 15ul of Fluo Flu Cal Substrate (Diagnostica Stago) was then added immediately and the microplate was read for 90 consecutive minutes. The measured real-time thrombin concentration values ​​were plotted against time to obtain a thrombogram for each concentration of test substance used.

[0162] TGA determination with tissue factor Thrombin generation profiles were determined on a Thermo Scientific Hemker Thrombinoscope in the following manner: A total of 55ul of pooled normal human plasma was added to the wells of a microplate at 37°C. 5ul of two-fold serially diluted test substances (antibodies or small molecule inhibitors) in PBS were then added to the wells of the microplate and allowed to incubate for 30 minutes. 15ul of tissue factor PPP reagent (Diagnostica Stago) was then added to the wells and allowed to incubate for 45 minutes. 15ul of Fluo Flu Cal substrate (Diagnostica Stago) was then added immediately and the microplate was read for 90 consecutive minutes. The measured real-time thrombin concentration values ​​were plotted against time to obtain a thrombogram for each concentration of test substance used.

[0163] result Dose-response curves were generated to determine the effect of each drug on plasma aPTT and PT. An IgG4 isotype control antibody had no effect on aPTT or PT. Anti-FXII / FXIIa antibodies (mAb26036, mAb26048, mAb26049, and mAb26076) prolonged the aPTT without increasing the PT. Apixaban, a clinically approved anticoagulant FXa inhibitor, prolonged both the aPTT and PT at μM concentrations. Comparator 1 prolonged the aPTT without increasing the PT. The efficiency of a drug to inhibit coagulation activity is measured by any "doubling time" concentration or C 2xt These estimated C 2xt The values ​​(ie, the curves across the "doubling time line") are listed in Table 8. [Table 8]

[0164] Antibodies mAb26036, mAb26048, and mAb26049 have C values ​​below 200 nM. 2xtApixaban reached aPTT C at 7 uM, whereas mAb26076 required 250 nM. None of the antibodies tested were found to double the PT clotting time up to 4 uM. 2xt This is the result of PT C 2xt The concentration of 3.5uM required to achieve aPTT C 2xt 250 nM was required to reach PT C 2xt did not reach.

[0165] Antibodies were evaluated for their ability to inhibit thrombin generation when plasma was challenged with ellagic acid or tissue factor (i.e., extended time to detection of thrombin = lag time, reduction in thrombin peak, and reduction in total amount of thrombin generated = endogenous thrombin generation potential). The isotype control had no effect on thrombin generation. The antibody showed a slight reduction in thrombin generation at 125 nM, but significantly or completely inhibited thrombin production at concentrations of 250 nM and above, indicating that the antibody suppresses activation of the intrinsic pathway that then prevents thrombin generation. Apixaban showed a dose-dependent reduction in thrombin generation, but even at the highest dose used (500 nM), it was unable to reach a doubling of the lag time or halving the ETP or peak. Comparator 1 showed a dose-dependent effect on thrombin generation with almost complete inhibition at 500 nM. Tissue factor-induced thrombin generation was not affected by the control isotype antibody. The antibody did not inhibit tissue factor-induced thrombin generation. Apixaban inhibited thrombin generation in a dose-dependent manner when induced by tissue factor. Comparator 1 had no effect on tissue factor-induced thrombin generation. The concentrations of test substances required to increase the lag time by 2-fold and halve the peak thrombin and total thrombin generation when coagulation was activated by ellagic acid or tissue factor are summarized in Table 9. [Table 9]

[0166] The above results demonstrate that the exemplified antibodies inhibit thrombin generation via the intrinsic pathway without inhibiting the extrinsic pathway.

[0167] The present invention should not be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will be apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to be included within the scope of the appended claims.

Claims

1. A human antibody or antigen-binding fragment thereof that specifically binds to factor XII (FXII), the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR); wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise a set of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 4, 6, 8, 12, 14 and 16, respectively; (b) SEQ ID NOs: 20, 22, 24, 28, 30 and 32, respectively; (c) SEQ ID NOs: 36, 38, 40, 44, 46 and 48, respectively; and (d) SEQ ID NOs: 52, 54, 56, 60, 62 and 64, respectively; An antibody or an antigen-binding fragment thereof.

2. 2. The antibody or antigen-binding fragment thereof of claim 1, having the following characteristics: (a) is a fully human monoclonal antibody; (b) binds to activated factor XII (FXIIa); (c) a dissociation constant (K) of less than 3.5 nM at 25° C. as measured by surface plasmon resonance assay. Ｄ ) and binds to FXII; (d) a K of less than 17 nM at 37° C. as measured in a surface plasmon resonance assay. Ｄ and binds to FXII. (e) a K of less than 5 nM as measured in a surface plasmon resonance assay Ｄ and binds to FXIIa. (f) a K of less than 6.5 nM as measured in a surface plasmon resonance assay. Ｄ and binds to FXIIa. (g) blocks thrombin generation by the intrinsic pathway at concentrations less than 250 nM as measured by a functional plasma assay; and (h) blocking thrombin generation via the intrinsic pathway without blocking thrombin generation via the extrinsic pathway, as measured by a functional plasma assay.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34 and 50.

4. The antibody or antigen-binding fragment thereof of claim 3, wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42 and 58.

5. The antibody or antigen-binding fragment thereof described in claim 1, comprising an amino acid sequence pair of HCVR and LCVR selected from the group consisting of SEQ ID NOs: 2 and 10, respectively, SEQ ID NOs: 18 and 26, respectively, SEQ ID NOs: 34 and 42, respectively, and SEQ ID NOs: 50 and 58, respectively.

6. An antibody or antigen-binding fragment thereof that binds to one or both of FXII and FXIIa, the antibody or antigen-binding fragment thereof comprising three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within HCVR and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within LCVR; the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are (a) SEQ ID NOs: 4, 6, 8, 12, 14 and 16, respectively; (b) SEQ ID NOs: 20, 22, 24, 28, 30 and 32, respectively; (c) SEQ ID NOs: 36, 38, 40, 44, 46, and 48, respectively; and (d) SEQ ID NOs: 52, 54, 56, 60, 62 and 64, respectively; The set of amino acid sequences is selected from the group consisting of the HCVR comprises an amino acid sequence having at least 90% identity to an entire amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; The LCVR comprises an amino acid sequence having at least 90% identity to an entire amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; An antibody or an antigen-binding fragment thereof.

7. 7. The antibody or antigen-binding fragment thereof of claim 6, wherein: the HCVR comprises an amino acid sequence having at least 95% identity to an entire amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; The LCVR comprises an amino acid sequence having at least 95% identity to an entire amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; An antibody or an antigen-binding fragment thereof.

8. 7. The antibody or antigen-binding fragment thereof of claim 6, wherein: the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; The LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; An antibody or an antigen-binding fragment thereof.

9. An antibody or antigen-binding fragment thereof that binds to one or both of FXII and FXIIa, the antibody or antigen-binding fragment thereof comprising three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within HCVR and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within LCVR; the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are (a) SEQ ID NOs: 4, 6, 8, 12, 14 and 16, respectively; (b) SEQ ID NOs: 20, 22, 24, 28, 30 and 32, respectively; (c) SEQ ID NOs: 36, 38, 40, 44, 46, and 48, respectively; and (d) SEQ ID NOs: 52, 54, 56, 60, 62 and 64, respectively; The set of amino acid sequences is selected from the group consisting of the HCVR comprises an amino acid sequence having no more than 12 amino acid substitutions in an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; The LCVR comprises an amino acid sequence having 10 or less amino acid substitutions in an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58; An antibody or an antigen-binding fragment thereof.

10. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an HCVR having the amino acid sequence of SEQ ID NO:

2.

11. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an HCVR having the amino acid sequence of SEQ ID NO:

18.

12. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an HCVR having the amino acid sequence of SEQ ID NO:

34.

13. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an HCVR having the amino acid sequence of SEQ ID NO:

50.

14. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an LCVR having the amino acid sequence of SEQ ID NO:

10.

15. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an LCVR having the amino acid sequence of SEQ ID NO:

26.

16. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an LCVR having the amino acid sequence of SEQ ID NO:

42.

17. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, comprising an LCVR having the amino acid sequence of SEQ ID NO:

58.

18. An antibody or antigen-binding fragment thereof according to any one of claims 6 to 10 and 14, comprising three CDRs contained within the HCVR of SEQ ID NO:2 and three CDRs contained within the LCVR of SEQ ID NO:

10.

19. An antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, 11 and 15, comprising three CDRs contained within the HCVR of SEQ ID NO: 18 and three CDRs contained within the LCVR of SEQ ID NO:

26.

20. An antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, 12 and 16, comprising three CDRs contained within the HCVR of SEQ ID NO: 34 and three CDRs contained within the LCVR of SEQ ID NO:

42.

21. The antibody or antigen-binding fragment thereof of any one of claims 6 to 9, 13 and 17, comprising three CDRs contained within the HCVR of SEQ ID NO:50 and three CDRs contained within the LCVR of SEQ ID NO:

58.

22. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 10, 14 and 18, comprising the amino acid sequence pair of HCVR and LCVR of SEQ ID NOs: 2 and 10, respectively.

23. An antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, 11, 15 and 19, comprising the amino acid sequence pair of HCVR and LCVR of SEQ ID NOs: 18 and 26, respectively.

24. The antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, 12, 16 and 20, comprising the amino acid sequence pair of HCVR and LCVR of SEQ ID NOs: 34 and 42, respectively.

25. An antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, 13, 17 and 21, comprising the amino acid sequence pair of HCVR and LCVR of SEQ ID NOs: 50 and 58, respectively.

26. 1. An isolated monoclonal antibody or antigen-binding fragment thereof that blocks cleavage of factor XII into FXIIa and FXIIb, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR); An isolated monoclonal antibody or antigen-binding fragment thereof, wherein the HCVR and LCVR have amino acid sequences consisting of a set of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, respectively; (b) SEQ ID NOs: 18 and 26, respectively; (c) SEQ ID NOs: 34 and 42, respectively; and (d) SEQ ID NOs: 50 and 58, respectively.

27. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that binds to one or both of FXII and FXIIa described in any one of claims 1 to 26, and a pharma- ceutically acceptable carrier or diluent.

28. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the amino acid sequence pair of HCVR and LCVR of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 and 18 to 26.

29. A vector comprising the polynucleotide sequence of claim 28.

30. A cell expressing the vector of claim 29.

31. A method for producing an antibody or antigen-binding fragment thereof that binds to one or both of FXII and FXIIa, comprising growing a cell described in claim 30 containing a vector comprising the isolated polynucleotide molecule described in claim 28 or a vector described in claim 29 under conditions that allow production of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof so produced.

32. 32. The method of claim 31, further comprising formulating the antibody or antigen-binding fragment thereof as a pharmaceutical composition comprising an acceptable carrier.

33. A pharmaceutical composition for preventing the formation of thrombi or for treating a subject at risk of thrombi formation, comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 26.

34. 34. The pharmaceutical composition of claim 33, wherein the subject has a disease, disorder or condition selected from the group consisting of venous thrombosis, arterial thrombosis, device thrombosis, thromboembolism, hereditary angioedema, stroke, thrombotic predisposition, cardiac ischemia, atherosclerotic plaque rupture, use of mechanical valve prostheses, use of blood-contacting medical devices, use of blood-contacting extracorporeal circuits, venous thromboembolism, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, Budd-Chiari syndrome, Paget-Schletter disease, renal vein thrombosis, cerebral venous sinus thrombosis, jugular vein thrombosis, cavernous sinus thrombosis, hepatic artery thrombosis, lower limb ischemia, and myocardial infarction.

35. 35. The pharmaceutical composition of claim 33 or 34, wherein the pharmaceutical composition is administered prophylactically or therapeutically to the subject in need thereof.

36. The pharmaceutical composition according to any one of claims 33 to 35, characterized in that the pharmaceutical composition is administered in combination with a second therapeutic agent.

37. 37. The pharmaceutical composition of claim 36, wherein the second therapeutic agent is selected from the group consisting of anticoagulants, direct thrombin inhibitors, thrombolytic drugs, fibrinolytic drugs, antiplatelet drugs, anti-inflammatory drugs, antihypertensive drugs, a second anti-FXII antibody, lipid-lowering drugs, mechanical clot retrieval, catheter-induced thrombolysis, compression stockings, and surgery.

38. The pharmaceutical composition according to any one of claims 33 to 37, characterized in that the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally or intramuscularly.

Images